[1] 金宇, 刘晓玲, 黄怡丹. 免疫球蛋白和自身抗体在乙型肝炎肝硬化发病和进展中的表达及与预后的关系[J]. 中国现代医学杂志,2023,33(4):56-61. [2] 张云, 尹伟, 王华, 等. 失代偿期肝硬化急性肾损伤患者急性肾损伤进展的危险因素[J]. 中华传染病杂志,2022,40(11):673-678. [3] 冯婧, 张鹏, 吴雪, 等. 失代偿性肝硬化急性肾损伤进展为慢性肾脏病的临床特征及其对预后的影响[J]. 中华消化杂志,2021,41(12):823-828. [4] Yu J T, Hu X W, Yang Q, et al. Insulin-like growth factor binding protein 7 promotes acute kidney injury by alleviating poly ADP ribose polymerase 1 degradation[J]. Kidney Int, 2022, 102(4):828-844. [5] Shoeib S M, Hassan A, Habeeb E, et al. Urinary insulin-like growth factor-binding protein 7 (IGFBp7), urinary tissue inhibitor of matrix metalloproteinase 2 (TIMP2), and serum transgelin as novel biomarkers of kidney injury in multiple myeloma[J]. Indian J Hematol Blood Transfus,2024,40(2):246-254. [6] 韩焕钦, 欧进军, 冯冰, 等. 尿IGFBP7及TIMP-2在失代偿期乙型肝炎肝硬化急性肾损伤中的应用价值[J]. 中华肝脏病杂志,2020,28(9):760-765. [7] Guzmán C, Bautista-Ubaldo M G, Campos-Espinosa A, et al. Insulin-like growth factor binding proteins and cellular senescence are involved in the progression of non-alcoholic fatty liver disease and fibrosis in a mouse model[J]. Medicina (Kaunas), 2024, 60(3):429. [8] 中华医学会肝病学分会、中华医学会感染病学分会. 慢性乙型肝炎防治指南[J]. 中华内科杂志,2006,45(2):162-170. [9] Angeli P, Gines P, Wong F, et al. Diagnosis and management of acute kidney injury in patients with cirrhosis: revised consensus recommendations of the International Club of Ascites[J]. Gut, 2015, 64(4):531-537. [10] 陈媛美, 刘锦, 朱传武, 等. 乙型肝炎病毒整合DNA在慢性乙型肝炎中的作用研究进展[J]. 中华肝脏病杂志,2024,32(2):164-167. [11] Kanduri S R, Velez J C Q. Kidney dysfunction in the setting of liver failure: core curriculum 2024[J]. Am J Kidney Dis, 2024, 83(3):386-401. [12] Bai Z, Fang F, Xu Z, et al. Serum and urine FGF23 and IGFBP-7 for the prediction of acute kidney injury in critically ill children[J]. BMC Pediatr, 2018, 18(1):192. [13] Wen Y, Parikh C R. Current concepts and advances in biomarkers of acute kidney injury[J]. Crit Rev Clin Lab Sci, 2021, 58(5):354-368. [14] Téllez L, Albillos A. Non-selective beta-blockers in patients with ascites: the complex interplay among the liver, kidney and heart[J]. Liver Int, 2022, 42(4):749-761. [15] Baiges A, Hernández-Gea V. Management of liver decompensation in advanced chronic liver disease: ascites, hyponatremia, and gastroesophageal variceal bleeding[J]. Clin Drug Investig, 2022, 42(Suppl 1):25-31. [16] Gligorijević N, Minić S, Nedić O. Structural changes of proteins in liver cirrhosis and consequential changes in their function[J]. World J Gastroenterol, 2022, 28(29):3780-3792. [17] Peng M J, Guo X Q, Zhang W L, et al. Effect of pegylated interferon-α2b add-on therapy on renal function in chronic hepatitis B patients: a real-world experience[J]. Front Microbiol, 2022, 13:980250. [18] 褚丽, 任传路, 丁俊, 等. TG/Cys-C联合MDA水平在2型糖尿病合并肾病患者中的诊断价值[J]. 河北医科大学学报,2024,45(3):368-372. [19] Hidayati E L, Utami M D, Rohsiswatmo R, et al. Cystatin C compared to serum creatinine as a marker of acute kidney injury in critically ill neonates[J]. Pediatr Nephrol, 2021, 36(1):181-186. [20] Sakyi S A, Ephraim R K D, Adoba P, et al. Tissue inhibitor metalloproteinase 2 (TIMP-2) and insulin-like growth factor binding protein 7 (IGFBP7) best predicts the development of acute kidney injury[J]. Heliyon, 2021, 7(9):e07960. [21] Woziwodzka K, Małyszko J, Koc-żórawska E, et al. Renal impairment detectors: IGFBP-7 and NGAL as tubular injury markers in multiple myeloma patients[J]. Medicina (Kaunas), 2021, 57(12):1348. [22] 邹晓彪, 包维为, 黄晓莹, 等. 尿基质金属酶蛋白抑制剂-2和胰岛素样生长因子结合蛋白7联合检测在对比剂诱导急性肾损伤中的早期预测作用[J]. 临床肾脏病杂志,2022,22(3):221-227. [23] Ganda I J, Kasri Y, Susanti M, et al. Kidney injury molecule type-1, interleukin-18, and insulin-like growth factor binding protein 7 levels in urine to predict acute kidney injury in pediatric sepsis[J]. Front Pediatr, 2022, 10:1024713. [24] Martínez-Castillo M, Rosique-Oramas D, Medina-Avila Z, et al. Differential production of insulin-like growth factor-binding proteins in liver fibrosis progression[J]. Mol Cell Biochem, 2020, 469(1-2):65-75. |